These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 36562802)
1. See clearer: survey on the subjective and objective information levels as well as perception and information transfer using virtual reality headsets in patients with diabetic macular edema receiving anti-VEGF treatment. Enders C; Duncker T; Schürks M; Scholz P; Dörner J; Müller C; Wachtlin J; Lommatzsch A Graefes Arch Clin Exp Ophthalmol; 2023 Jun; 261(6):1563-1570. PubMed ID: 36562802 [TBL] [Abstract][Full Text] [Related]
2. Impact of systemic parameters before commencing anti-vascular endothelial growth factor therapy for diabetic macular edema - Pan-Indian survey of retina specialists. Shanmugam PM; Shah P; Ramanjulu R; Mishra D Indian J Ophthalmol; 2021 Nov; 69(11):3273-3278. PubMed ID: 34708786 [TBL] [Abstract][Full Text] [Related]
10. Association of metformin treatment with enhanced effect of anti-VEGF agents in diabetic macular edema patients. Shao Y; Wang M; Zhu Y; Li X; Liu J Acta Diabetol; 2022 Apr; 59(4):553-559. PubMed ID: 35034186 [TBL] [Abstract][Full Text] [Related]
11. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK; JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949 [TBL] [Abstract][Full Text] [Related]
12. Treatment results of diabetic macular edema with different choroidal thickness with intravitreal anti vascular endothelial growth factor. Savur F; Kaldırım H; Atalay K; Öğreden T; Hayat ŞÇ BMC Ophthalmol; 2022 Dec; 22(1):508. PubMed ID: 36550418 [TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections. Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy. Wilkins CS; Sobol EK; Lema GM; Lee JG; Rosen RB; Deobhakta A Eur J Ophthalmol; 2022 Sep; 32(5):NP37-NP41. PubMed ID: 33757333 [TBL] [Abstract][Full Text] [Related]
16. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response. Lee J; Moon BG; Cho AR; Yoon YH Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201 [TBL] [Abstract][Full Text] [Related]
17. Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema. Liu MM; Wolfson Y; Bressler SB; Do DV; Ying HS; Bressler NM Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1370-7. PubMed ID: 24526445 [TBL] [Abstract][Full Text] [Related]
18. Adherence to Intravitreal Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs in Diabetic Macular Edema in an Egyptian Population: A Health Belief Model. Habib AE; Abdel-Kader AA; Eissa IM; Awadein A Curr Eye Res; 2019 Mar; 44(3):303-310. PubMed ID: 30383436 [TBL] [Abstract][Full Text] [Related]
19. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE. Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914 [TBL] [Abstract][Full Text] [Related]
20. Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management. Cicinelli MV; Rabiolo A; Zollet P; Capone L; Lattanzio R; Bandello F Am J Ophthalmol; 2020 Jul; 215():14-24. PubMed ID: 32209341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]